MedPath

Lacosamide

Generic Name
Lacosamide
Brand Names
Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB
Drug Type
Small Molecule
Chemical Formula
C13H18N2O3
CAS Number
175481-36-4
Unique Ingredient Identifier
563KS2PQY5

Overview

Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.

Background

Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.

Indication

Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.

Associated Conditions

  • Epilepsy, Primary Generalized Tonic-Clonic Seizures
  • Partial-Onset Seizures
  • Status Epilepticus

FDA Approved Products

Lacosamide
Manufacturer:Sun Pharmaceutical Industries, Inc.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2023/11/20
NDC:47335-918
Lacosamide
Manufacturer:Westminster Pharmaceuticals, LLC
Route:ORAL
Strength:50 mg in 1 1
Approved: 2023/06/01
NDC:69367-348
Lacosamide
Manufacturer:Alembic Pharmaceuticals Limited
Route:ORAL
Strength:100 mg in 1 1
Approved: 2022/03/28
NDC:46708-172
Lacosamide
Manufacturer:Alembic Pharmaceuticals Limited
Route:ORAL
Strength:150 mg in 1 1
Approved: 2022/03/28
NDC:46708-173
Lacosamide
Manufacturer:AvKARE
Route:ORAL
Strength:150 mg in 1 1
Approved: 2024/01/10
NDC:42291-862

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath